Offering statins to people with HIV to lower the risk of heart disease poses particular challenges for low- and middle-income countries and requires investment in order to deliver the benefits identified in a large international clinical trial of the drugs.
In a commentary published in December 2023 in Clinical Infectious Diseases, physicians from the United States and South Africa ask how the results of the REPRIEVE study will change clinical practice in low- and middle-income countries.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
ACTG launches landmark study evaluating treatments for depressive disorders with or without mild neurocognitive disorder among people living with HIV
-
BBC: World’s biggest condom maker set to raise prices due to Iran war
-
Florida International University: HIV disrupts lung “clock,” raising COPD and emphysema risk
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.